Consolidation in Diagnostics: AmeriPath vs. Dianon
Executive Summary
Anatomic pathology is consolidating rapidly due to changes in reimbursement and the looming presence of managed care. The pioneering players, AmeriPath and Dianon, are taking radically different approaches to gaining market share.
You may also be interested in...
Anatomic Pathology: Aggressive Buyers or Anxious Seller?
LabCorp.'s proposed purchase of Dianon Systems, followed by the announcement of Welsh Carson's bid for AmeriPath, reflect different paths taken by two fierce competitors.They are also the inevitable consequence of rapid laboratory consolidation at the national level. LCA wants Dianon so that it can expand its position in cancer testing. Welsh Carson, in contrast, is a financial buyer who would have to "clean up" AmeriPath, which has run into difficulties due to its physician practice management business model.
Anatomic Pathology: Aggressive Buyers or Anxious Seller?
LabCorp.'s proposed purchase of Dianon Systems, followed by the announcement of Welsh Carson's bid for AmeriPath, reflect different paths taken by two fierce competitors.They are also the inevitable consequence of rapid laboratory consolidation at the national level. LCA wants Dianon so that it can expand its position in cancer testing. Welsh Carson, in contrast, is a financial buyer who would have to "clean up" AmeriPath, which has run into difficulties due to its physician practice management business model.
Further Consolidation in Anatomic Pathology
Dianon System's purchase in June of UroCor was hardly surprising, coming after three years of discussions between the two companies. The purchase of UroCor, a disease management company, will fortify Dianon's already strong franchise in urology clinical diagnostics testing. The deal, a stock-for-stock transaction valued at about $180 million, merges two complementary businesses, offering opportunities for synergies and leveraging of operations.